Company announcements, press releases and news coverage
Biotech attends inter-Government conference in Lusaka
Members of the Biotech International sales team attended the Commonwealth Governmental conference in Lusaka last week. Delegates included a number of presidents and prime ministers from African and Commonwealth countries, together with various ministers of health and science & technology. A number of useful contacts have been established, resulting in at least two offers of talks and introductions to potential distributors in territories in Africa and the Far East.
6 August 2008
---------------------------------------------------------------------------------------
Copy of press release to newspapers in Zambia
UK biotech company chooses to launch new product in Zambia in the fight against malaria.
A revolutionary insecticide coating designed for internal walls of schools, hospitals, offices and houses is to be launched in Zambia. Once painted onto walls, mosquitoes die after touching the surface.
Biotech International Ltd, a UK research company, is hoping to find a partner in Zambia to help in the fight against vector-borne diseases such as malaria and chikungunya.
Mozzi-Mort is a clear coating that will remain active for at least two years and is harmless to humans and other mammals. It has been independently tested by the London School of Hygiene & Tropical Medicine, and is now being registered in countries affected by insect borne diseases.
James Vintcent, Director of Sales for Biotech International Ltd, is in Lusaka to attend the government conference Smart Partnership Mulungushi Dialogue and is also hoping to find the right groups to help Zambia and Southern Africa reduce its malaria burden.
Mr. Vintcent said “This is a fantastic opportunity for Zambia, and we are convinced that this unique product, a result of eight years of research, can make a real difference to the social and economic situation in the country. Losses due to vector-borne diseases such as malaria can be measured in terms of human misery and suffering as well as economic losses to companies and the country. This product can help reduce both.”
End.
--------------------------------------------------------------------------------------------------------------
Indian launch exceeds expectations as Ministers back Biotech
Two Government Ministers of India lent their support to the launch of Biotech products in Delhi last week. Dr. Akhilesh Prasad Singh, Minister of State in the Ministry of Agriculture and Lt. Gen J R Bhardwaj, of the National Disaster Management Authority, both endorsed Biotech products for use in India. Each addressed the launch, held at the Intercontinental Hotel, New Delhi on 8th May and attended by press and TV.
The event began with the formal completion of the joint venture agreement between Agri Gold Group and Biotech. Agri Gold is an Indian company with direct representation throughout India and the region. It has a first class record in the promotion, marketing and merchandising of healthcare products. To that extent it has, on our behalf, developed EnviroCair for use in an aerosol spray can and engineered an improved diffuser box .It also intends to provide the funding for the development of further vertical products with a consequential increase in Biotech’s value.
John Coombs, CEO, said “The Agri Gold partnership opens up the whole of India to Biotech and, as Agri Gold have over 1,000 direct sub distributors, I fully expect that in time every business, institution and home will benefit from the use of EnviroCair and Mozzi-Mort.”
The Intercontinental presentation was attended by over 80 of the sub distributors and representatives of the national press. The Biotech team was headed by John Coombs, Ian Heard and James Vintcent; Agri Gold by V R Rao, Chairman, and. Standard Organics (Anglo-Indian intermediary company).by Udaya Chembottu and Manjit Kailey.
John Coombs, CEO said “The presence of the two government ministers shows how seriously India takes its responsibilities towards its citizens and the recognition by the Indian authorities of the social and economic threat that viruses, bacteria and insect borne disease pose - a lesson that is yet to be learnt by some European governments. I am most grateful to the people of India for their enterprise and initiative and as we develop I fully expect India to act as a distribution and manufacturing hub for the region.”
The conference concluded with a detailed discussion on order processing, new product development and delivery.
Dr. Akhilesh Prasad Singh, |
John Coombs, Dr. Akhilesh Prasad |
Lt. Gen J R Bhardwaj addresses |
---------------------------------------------------------------------------------------------------------------------------
Biotech International Ltd launches Philippines distribution
Biotech.Philippines Inc. held a presentation to over 150 invited guests at the Renaissance Hotel in Manila on Friday 18th April to launch Mozzi-Mort and EnviroCair products.
Speakers included
• Dr. Nerissa Nocon Dominguez, of the World Health Organization, Communicable
Diseases Section
• Dr Eric Tayag, Director, National Epidemiology Center, Philippines
Department of Health
• Dr. Nigel Hill, Head of the Disease Control & Vector Biology Unit,
London School of Hygiene & Tropical Medicine
• Dr. Peter Cooke, consultant chemist, Biotech International Ltd
• His Excellency Mr. Peter Beckingham, British Ambassador to the Philippines
Biotech.Philippines Inc. has established an office with warehousing and distribution facilities in Manila, including a bottling and repackaging plant, in preparation for expected orders resulting from the launch.
.  |
Discussions are already taking place with members of the Philippines armed forces and a number of city Mayors who attended the launch. Department of Health officials have also indicated that the purchase of Mozzi-Mort and EnviroCair products will have to be accommodated in forthcoming budgets as a requirement for use in hospitals.
Amongst those who attended the launch were a number of candidate distributors for countries in the Asia Pacific region, including Thailand, Taiwan, Malaysia and Singapore. At a separate potential distributor meeting, these applicants were made aware of the financial commitments necessary for gaining approval as Biotech distributors. Minimum orders will be required, amounting to approximately £600,000 per territory per annum.
John Coombs, CEO Biotech International Ltd, said “I see the Philippines
as the centre of a South East Asian marketing programme which may eventually
include manufacturing for the region.”
---------------------------------------------------------------------------------------------------------------------------
Share issue
Shareholders are advised that they should now be in receipt of an official document offering a subscription to purchase shares at 85p. This is strictly for current shareholders. It is only available through the company and no broker has been appointed to handle this issue. If you have not received the documentation, please write to:
Subscription Offer
Biocide International PLC
14 Berkeley Mews
London
W1H 7AX
As with all investments, you should take independent professional advice.
1 April 2008
---------------------------------------------------------------------------------------------------------------------------
Investment into Company
Biocide International PLC is pleased to announce that Allianz Insurance PLC has made a substantial investment in the company at 80p per share. John Coombs, CEO, says “We welcome this significant investment into the Company by Allianz, as it now allows us the opportunity to develop fully the increasing demand for Biotech products around the world.”
28 January 2008
Please note
Your attention is drawn to the paragraph headed Investment on our legal
page which reads as follows:-
Investment
The information contained in the website is not an invitation to invest in
the shares, or any other products or services or otherwise deal in these or
enter into a contract with Biocide International PLC or any other company.
The information provided should not be relied upon in connection with any
investment decision.
The company continuously reviews its capital requirements. There is currently
no broker or investment bank acting for or on behalf of the company. The Board
are considering a number of proposals which may or may not include a listing
on a Recognised Investment Exchange. Any such listing would be subject to
FSA regulatory approval.
------------------------------------------------------------------------------------------------------------------------
Winter newsletter - click to download